Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Diabetes / Metabolic Neurology Rheumatology Women's Health Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Clinical Trial ● Currently Recruiting Non-phase study NCT07721779

Is the Use of a Steam Mask an Effective Treatment for Paediatric Chalazion in Comparison to Traditional Warm Compresses?

Is the Use of a Steam Mask an Effective Treatment for Paediatric Chalazion in Comparison to Traditional Warm Compresses? — Recruiting • Non-phase study • Oncology • NCT07721779.

📅 23 Jul 2026 ⏱ 1 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
Phase
Non-phase study
NCT ID
NCT07721779
Sponsor
University of Sheffield
Start
2026-03-10
ClinicaliQ Trial Snapshot
  • Is the Use of a Steam Mask an Effective Treatment for Paediatric Chalazion in Comparison to Traditional Warm Compresses? — Recruiting • Non-phase study • Oncology • NCT07721779.
  • What is being tested: This trial compares the effectiveness of a steam mask versus traditional warm compresses as treatments for chalazion (a common eyelid inflammatory condition) in children.
  • Patient eligibility overview: The study focuses on paediatric patients diagnosed with chalazion who are suitable candidates for conservative (non-surgical) management with heat-based therapies.
Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

Is the use of a steam mask an effective treatment for paediatric chalazion in comparison to traditional warm compresses? This study will aim to assess the difference between these two methods.

Eligibility Snapshot
  • : * Diagnosed chalazion (isolated or multiple). * Aged between 5 -

Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Clinical Brief
‘My cancer spread while I waited months for surgery’: The cost of England’s cancer wait times
Oncology · BBC Health · 10 Sep 2026
England's cancer surgery waiting times have deteriorated despite government initiatives aimed at improving them, with patients experiencing significant delays that may allow…
View brief →
Guideline
Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer
Oncology · 16 Jun 2026
First-line treatment option: Cemiplimab combined with platinum-based chemotherapy is recommended by NICE for patients with untreated advanced non-small-cell lung cancer (NSCLC), offering…
View guideline →
Guideline
Cemiplimab for treating recurrent or metastatic cervical cancer that has progressed on or after platinum-based chemotherapy
Oncology · 09 Jul 2026
Cemiplimab is recommended as a treatment option for patients with recurrent or metastatic cervical cancer only after progression on or following platinum-based…
View guideline →
Guideline
Mirvetuximab soravtansine for treating folate receptor-alpha-positive platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer
Oncology · 24 Jun 2026
Mirvetuximab soravtansine is recommended for platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients with folate receptor-alpha (FRα) positivity—confirm FRα…
View guideline →
Guideline
Durvalumab with platinum-based chemotherapy, then with or without olaparib, for untreated advanced or recurrent endometrial cancer
Oncology · 09 Sep 2026
Durvalumab combined with platinum-based chemotherapy is the recommended first-line treatment for untreated advanced or recurrent endometrial cancer, with olaparib addition considered based…
View guideline →
Clinical Brief
Inside Health
Oncology · BBC Health · 28 Jul 2026
Inflammation emerges as a common pathological mechanism across diverse conditions including cancer and neurodegenerative diseases, offering potential for unified therapeutic approaches targeting…
View brief →